This product is only available in select locations. Please select the location where you would like this product to be shipped to see availability.
TruSight Oncology 500 ctDNA v2 plus Velsera Interpretation Report, for Use with NovaSeq 6000 S2 Flow Cell (24 samples)
20105907
TruSight Oncology 500 ctDNA v2 plus Velsera Interpretation Report, for Use with NovaSeq 6000 S4 Flow Cell (24 samples)
20105908
TruSight Oncology 500 ctDNA Kit plus Velsera Interpretation Report (16 indexes, 48 Samples)
20043410
TruSight Oncology 500 ctDNA Kit for use with NovaSeq 6000 S2 plus Velsera interpretation report (16 indexes, 48 samples)
20102000
TruSight Oncology 500 ctDNA Kit for use with NovaSeq 6000 S4 plus Velsera interpretation report (16 indexes, 48 samples)
20102001
Illumina Connected Insights-Annual Subscription
20090137
Illumina Connected Insights‒Oncology Genome Equivalent Sample-VCF
20090138
Illumina Connected Insights‒Training and Onboarding
20092376
Informatics Professional Services
20071787
TruSight Oncology 500 ctDNA v2 is a pan-cancer NGS assay that enables in-house comprehensive genomic profiling (CGP) of circulating tumor DNA (ctDNA) in blood plasma for research.
Compatibility on the NovaSeq 6000 with NovaSeq 6000Dx (in RUO mode) and NovaSeq X coming in 2024!
Low-level biomarker detection
Achieve sensitive and accurate detection (0.2% VAF for SNVs) with low inputs (20 ng) using UMI-based hybrid-capture library prep and deep sequencing.
Integrated bioinformatics
DRAGEN secondary analysis powers a rapid variant calling algorithm on-premises or in the cloud with Illumina Connected Analytics. Access insights using integrated reporting with Illumina Connected Insights* or Velsera.
Streamlined workflow
Advanced chemistry and extensive workflow optimization enable a single-day library prep plus enrichment for a total turnaround time of <4 days. Automation-friendly kits and methods enable increased efficiencies.†
*Not available in all countries. Illumina Connected Insights supports user-defined tertiary analysis through API calls to third-party knowledge sources.
†Automation-friendly kits available in Q1 2024
Illumina improved the analysis of circulating tumors with TruSight Oncology ctDNA 500 v2. Learn about new features and benefits in the video.
Maximize chances of identifying an actionable alteration with the TruSight Oncology 500 product line.
Analyze circulating tumor DNA (ctDNA) in blood plasma with similar DNA panel content as TruSight Oncology 500.
Assess relevant DNA and RNA cancer biomarkers from FFPE tumor tissue, now including HRD through an accessory kit to assess the Genomic Instability Score (GIS)†
Batch up to 192 samples at a time while using the same panel content and tissue input type as TruSight Oncology 500.
†HRD is only available with the addition of the TruSight Oncology 500 HRD kit to the TruSight Oncology 500 kit. Not available in Japan.
Interested in learning more about the TSO 500 portfolio of products?
Download the overview brochureInstrument | Recommended Number of Samples | Read Length |
---|---|---|
NovaSeq 6000 System | 24 samples per run (S4 flow cell), 800M paired-end reads, 35,000x coverage | 2 × 150 bp |
NovaSeq 6000 System | 8 samples per run (S2 flow cell), 800M paired-end reads, 35,000x coverage | 2 × 150 bp |
TruSight Oncology 500 ctDNA v2 | TruSight Oncology 500 | TruSight Oncology 500 High-Throughput | |
---|---|---|---|
Cancer Type | Pan-Cancer, Solid Tumor | Pan-Cancer | Pan-Cancer |
Method | Target Enrichment, Target Enrichment, Targeted DNA Sequencing | Target Enrichment, Target Enrichment, Targeted DNA Sequencing, Targeted RNA Sequencing | Target Enrichment, Target Enrichment, Targeted DNA Sequencing, Targeted RNA Sequencing |
Nucleic Acid Type | DNA | RNA, DNA | RNA, DNA |
Specialized Sample Types | Blood, Circulating Tumor DNA | FFPE Tissue | FFPE Tissue |
Species Category | Human | Human | Human |
System Compatibility | NovaSeq 6000 | NextSeq 500, NextSeq 550, NextSeq 550Dx in Research Mode | NovaSeq 6000, NovaSeq 6000Dx in Research Mode |
Technology | Sequencing | Sequencing | Sequencing |
Variant Class | Copy Number Variants (CNVs), Insertions-Deletions (indels), Single Nucleotide Variants (SNVs) | Copy Number Variants (CNVs), Gene Fusions, Insertions-Deletions (indels), Single Nucleotide Variants (SNVs), Transcript Variants | Copy Number Variants (CNVs), Gene Fusions, Insertions-Deletions (indels), Single Nucleotide Variants (SNVs), Transcript Variants |
* Based on Pierian clinical knowledgebase, as of February 2023.
* NovaSeq 6000Dx System in RUO Mode requires a separate, stand-alone DRAGEN server for secondary analysis.
* NovaSeq X and NovaSeq 6000 Dx compatibility coming in 2024
Learn about this joint effort to accelerate the development of personalized treatments based on genomic information.
Learn moreSimplifying the process to identify applicable variants in oncology samples
Brochure | PDF 2 MB
Liquid Biopsy and NGS: Driving translational clinical research to the next level
Application Note | PDF < 1 MB
Technical Note | PDF | 2 versions
TruSight Oncology 500 ctDNA Gene List
product_file | EXCEL < 1 MB
Data analysis and reporting for the TruSight Oncology 500 portfolio
Product Information Sheet | PDF 1 MB
Data Sheet | PDF | 7 versions
TruSight Oncology 500 ctDNA v2
Data Sheet | PDF 1 MB
TruSight Oncology 500 ctDNA Support Documentation
DRAGEN TruSight Oncology 500 ctDNA Analysis Software v1.2 on ICA Documentation
TruSight Oncology 500 ctDNA Checklist Documentation
DRAGEN Analysis Workflows Product Documentation
DRAGEN TruSight Oncology 500 ctDNA Analysis Software v2.1.1 on ICA Documentation
TruSight Oncology 500 ctDNA Consumables & Equipment Documentation
TruSight Oncology 500 ctDNA Local App Documentation
TruSight Oncology 500 ctDNA v2 Product Documentation
DRAGEN TruSight Oncology 500 ctDNA Analysis Software v1.2 Documentation
DRAGEN TruSight Oncology 500 ctDNA Local Analysis Software v2.1 Documentation
DRAGEN TruSight Oncology 500 ctDNA v1.1 Local Analysis Software Documentation